Artios

Artios develops medicines that harness DNA Damage Response pathways, targeting DNA replication stress and synthetic lethality to treat cancer.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series D
Initial Investment Year
2025
Artios Portco Hover Image